| Trial ID # | IRCT2016- 022726788N1 |
| Phase | II |
| Drug Class | Signaling Pathway Inhibitors: PI3K-AKT-mTOR/mTOR |
| Drug Name | Metformin |
| Alternate Drug Names | Fortamet, Glucophage, Glumetza, Riomet |
| Drugs in Trial | Carboplatin, Metformin, Paclitaxel |
| Eligible Participant | Newly diagnosed stage I-III ovarian cancer |
| Patients Enrolled | 70 |
| Therapy Setting | First-line |
| Study Design | Open-Label, Randomized |
| Endpoints | RFS, evaluated per CA125 |
| Efficacy | CarboPt+Pac+Met (n=30) vs CarboPt+Pac (n=40): RFS: 48.0 vs 25.7 months 4-year rate of recurrence: 67.5 vs 13.3% |
| Clinically Significant Adverse Events | CarboPt+Pac+Met vs CarboPt+Pac: |
| Conclusion | Improved RFS with addition of metformin to carboplatin+paclitaxel in stage I-III patients |
| Reference | Hamedi B et al. Combination of Metformin and Chemotherapy Decreases the Recurrence Rates of Epithelial Ovarian Cancers: A Randomized Clinical Trial. Int J Cancer Manag (2018) 11(7): e11621 |